Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults (2025)
https://pubmed.ncbi.nlm.nih.gov/39608805/

Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study (2024)
https://pubmed.ncbi.nlm.nih.gov/38556921/

Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) (2024)
https://pubmed.ncbi.nlm.nih.gov/37955181/

Is JAK inhibitor the option to prevent difficult-to-manage axial spondyloarthritis? (2024)
https://pubmed.ncbi.nlm.nih.gov/39234892/

Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. (2023)
https://pubmed.ncbi.nlm.nih.gov/37787903/

Preface to practical procedures how to do. (2023)
https://pubmed.ncbi.nlm.nih.gov/37574370/

Current evidence and practical knowledge for ultrasound-guided procedures in rheumatology: Joint aspiration, injection, and other applications. (2023)
https://pubmed.ncbi.nlm.nih.gov/37248141/

Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2 (2023)
https://pubmed.ncbi.nlm.nih.gov/37191738/

Upadacitinib for moderate-to-severe atopic dermatitis, in adults and adolescents 12 years and older: review of international and Japanese populations. (2023)
https://pubmed.ncbi.nlm.nih.gov/36408603/

Management of psoriatic arthritis in patients with comorbidities: an updated literature review informing the 2021 GRAPPA treatment recommendations. (2023)
https://pubmed.ncbi.nlm.nih.gov/36319003/

4827-006 study group: Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study. (2023)
https://pubmed.ncbi.nlm.nih.gov/36130275/

Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study (2023)
https://pubmed.ncbi.nlm.nih.gov/36243812/

Axial Spondyloarthritis in Japan (2022)
https://pubmed.ncbi.nlm.nih.gov/35380380/

Clinical characteristics of patients with spondyloarthritis and inflammatory bowel disease versus inflammatory bowel disease-related arthritis (2022)
https://pubmed.ncbi.nlm.nih.gov/35532790/

Patient perceptions of psoriatic disease in Japan: Results from the Japanese subgroup of the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey (2022)
https://pubmed.ncbi.nlm.nih.gov/35624553/

Pro and contra: is synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) a spondyloarthritis variant? (2022)
https://pubmed.ncbi.nlm.nih.gov/35699334/

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension (2022)
https://pubmed.ncbi.nlm.nih.gov/35896281/

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial (2022)
https://pubmed.ncbi.nlm.nih.gov/35908570/

Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study (2022)
https://pubmed.ncbi.nlm.nih.gov/36130275/

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis (2022)
https://pubmed.ncbi.nlm.nih.gov/36171019/

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study (2022)
https://pubmed.ncbi.nlm.nih.gov/36243812/

Management of Psoriatic Arthritis in Patients With Comorbidities: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations (2022)
https://pubmed.ncbi.nlm.nih.gov/36319003/

A Nationwide Questionnaire Survey on the Prevalence of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in Japan (2021)
https://pubmed.ncbi.nlm.nih.gov/34755187/

SAPHO Syndrome and Pustulotic Arthro-Osteitis (PAO) (2021)
https://pubmed.ncbi.nlm.nih.gov/34967407/

Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study (2021)
https://pubmed.ncbi.nlm.nih.gov/34750246/

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study (2021)
https://pubmed.ncbi.nlm.nih.gov/34663636/

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1 (2021)
https://pubmed.ncbi.nlm.nih.gov/34636026/

Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study (2021)
https://pubmed.ncbi.nlm.nih.gov/34531305/

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension (2021)
https://pubmed.ncbi.nlm.nih.gov/34196498/

Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial” by Zhao and Huang (2021)
https://pubmed.ncbi.nlm.nih.gov/34172504/

Pustular Psoriasis and Associated Musculoskeletal Disorders (2021)
https://pubmed.ncbi.nlm.nih.gov/34074664/

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial (2021)
https://pubmed.ncbi.nlm.nih.gov/33827787/

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/33789011/

Clinical features of psoriatic arthritis (2021)
https://pubmed.ncbi.nlm.nih.gov/33744078/

Pustular Psoriasis and Associated Musculoskeletal Disorders (2021)
https://pubmed.ncbi.nlm.nih.gov/33722939/

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study (2021)
https://pubmed.ncbi.nlm.nih.gov/33462157/

The Diagnosis and Treatment of Adult Patients with SAPHO Syndrome: Controversies Revealed in a Multidisciplinary International Survey of Physicians (2021)
https://pubmed.ncbi.nlm.nih.gov/32974863/

Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study (2021)
https://pubmed.ncbi.nlm.nih.gov/34144387/

Reactive arthritis after COVID-19 infection (2020)
https://pubmed.ncbi.nlm.nih.gov/32763956/

Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J) (2020)
https://pubmed.ncbi.nlm.nih.gov/30334633/

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial (2019)
https://pubmed.ncbi.nlm.nih.gov/31732180/

2018 APLAR axial spondyloarthritis treatment recommendations (2019)
https://pubmed.ncbi.nlm.nih.gov/30816645/

Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World (2019)
https://pubmed.ncbi.nlm.nih.gov/30770497/

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1) (2018)
https://pubmed.ncbi.nlm.nih.gov/29945203/

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1) (2018)
https://pubmed.ncbi.nlm.nih.gov/29247148/

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1 (2017)
https://pubmed.ncbi.nlm.nih.gov/29299340/

Nail findings in patients with psoriatic arthritis: A cross-sectional study with special reference to transverse grooves (2017)
https://pubmed.ncbi.nlm.nih.gov/28666612/

Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study (2016)
https://pubmed.ncbi.nlm.nih.gov/26489703/

Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan (2015)
https://pubmed.ncbi.nlm.nih.gov/26077408/

Magnetic resonance angiography in psoriatic arthritis of the hand (2012)
https://pubmed.ncbi.nlm.nih.gov/22859531/

Clinical Images: iliopsoas bursa rupture mimicking psoas muscle abscess (2010)
https://pubmed.ncbi.nlm.nih.gov/20506348/

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis (2006)
https://pubmed.ncbi.nlm.nih.gov/17108350/

Syphilis mimicking Reiter’s syndrome in an HIV-positive patient (2006)
https://pubmed.ncbi.nlm.nih.gov/16909057/